Letitia Lensun

The Identification of 2-(1<i>H</i>-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-<i>d</i>]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer

Adrian Folkes, Khatereh Ahmadi, W. Alderton et al. · Journal of Medicinal Chemistry · 2008 · 739 citations · Full text

Pi3 Kinase, Chemoprevention Strategy, Pharmacotherapy +18

Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941

Florence I. Raynaud, Suzanne A. Eccles, Sonal Patel et al. · Molecular Cancer Therapeutics · 2009 · 270 citations · Full text

GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway

Jeffrey J. Wallin, Kyle A. Edgar, Jane Guan et al. · Molecular Cancer Therapeutics · 2011 · 226 citations

Chemoprevention Strategy, Cancer Biology, Pd Biomarkers +20

Functional characterization of a novel somatic oncogenic mutation of PIK3CB

Andrew Whale, Lucy Colman, Letitia Lensun et al. · Signal Transduction and Targeted Therapy · 2017 · 44 citations · Full text